Completed PHASE4 NCT00186329

BNP for Cardio-Renal Decompensation Syndrome (BNP-CARDS)

B-type Natriuretic Peptide for Cardio-Renal Decompensation Syndrome

Sponsor: Scios, Inc.

Conditions Congestive Heart Failure Exacerbation Renal Insufficiency

Interventions Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo

Updated 5 times since 2017 Last updated: Apr 24, 2015 Started: Mar 31, 2004 Completion: Oct 31, 2006

Listed as NCT00186329, this PHASE4 trial focuses on Congestive Heart Failure Exacerbation and Renal Insufficiency and remains completed. Sponsored by Scios, Inc., it has been updated 5 times since 2004, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Scios, Inc.
Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Stanford, United States